March 14, 2024
Exclusive Opportunity: Cell & Gene Therapy Consulting Session
Discover a unique opportunity to participate in one-on-one discussions with Premier Research experts. Our specialists in cell and gene therapy will be accessible on specific dates for personalized consultations. Seize this opportunity to acquire valuable insights. Secure your spot by signing up now.
Leading minds in the field who’ll be on hand to guide these discussions include:
- Kenneth Ndugga-Kabuye, M.D., FACMG, Vice President, Cell & Gene Therapy, who is an expert in the management and clinical development of rare genetic diseases.
- Daniel Zamfir, MBA, Executive Director, Program Strategy, Cell & Gene Therapy, who develops operational strategies for clients in the cell and gene space and rare diseases.
- Olu Aloba, Ph.D., Vice President, CMC Services, who is a leader in pharmaceutical research and development, pharmaceutical technology, and regulatory strategy.
- Jessica Merryfield, Executive Director, Cell & Gene Therapy, who advises, consults, plans, and directs the design and strategy for prospective and ongoing CGT studies.
- Greg Meyer, Vice President, Regulatory Affairs, who specializes in regulatory approvals, working on the development, submission, and commercialization of NMEs and 505(b)(2) products.
- Mimi Huang, Ph.D., Toxicologist, who is an expert in various nonclinical aspects of therapeutic product development.
- Elaina Haeuber, M.S., Senior Vice President, Oncology, who brings 20 years’ experience in delivering tailored and strategic clinical development programs.
- Plus, more! This is an unparalleled group of experts who will tailor the experience just for you.